Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZFAT antisense RNA 1 (ZFAT-AS1) is a long non-coding RNA expressed in human peripheral blood B-lymphocytes, among other tissues[1]. ZFAT-AS1 is transcribed antisense to the ZFAT gene and negatively regulates the truncated ZFAT isoform (TR-ZFAT) via epigenetic mechanisms, including recruitment of PRC2 and the induction of H3K27me3 modifications[3]. Its expression is subject to imprinting and monoallelic regulation, which is important for developmental and placental function in mammals[2]. A specific SNP in its promoter/3'-UTR (shared with TR-ZFAT) is linked to increased risk of autoimmune thyroid disease[1]. In glioma cells, ZFAT-AS1 overexpression suppresses cell proliferation, migration, and invasion, while promoting apoptosis, suggesting a role as a tumor suppressor lncRNA[3]. No drugs currently target ZFAT-AS1, but its expression level and associated SNP may serve as research biomarkers for disease susceptibility and pathogenesis[1][3][4][5].
Not applicable (No approved drugs target this RNA; however, its functional mechanism includes recruitment of PRC2 for transcriptional repression via H3K27me3)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZFAT antisense RNA 1 (ZFAT-AS1).